20/20 Biolabs, Inc. Common Stock (AIDX) — Capital Reinvestment Ratio
20/20 Biolabs, Inc. Common Stock (AIDX) has a Capital Reinvestment Ratio of 0.05x as of December 2022, meaning it reinvests 0% of its operating cash flow ($5.80 Million) in capital expenditures ($261.79K). Check how tangible is 20/20 Biolabs, Inc. Common Stock's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
20/20 Biolabs, Inc. Common Stock Capital Reinvestment Ratio (2022–2022)
This chart tracks 20/20 Biolabs, Inc. Common Stock's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see AIDX cash flow conversion.
Annual Capital Reinvestment Ratio for 20/20 Biolabs, Inc. Common Stock (2022–2022)
Year-by-year Capital Reinvestment Ratio for 20/20 Biolabs, Inc. Common Stock from 2022 to 2022. See 20/20 Biolabs, Inc. Common Stock free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.05x | $5.80 Million | $261.79K | — |